Neuropsychiatric Tolerability
Consistent Tolerability Profile Regardless of Baseline Neuropsychiatric Comorbidities
Post hoc subgroup analysis of treatment-naïve patients through 48 weeks1*
additional risk of study discontinuation due to adverse events related to SYMTUZA®
in patients with baseline NPCs1†‡
According to the DHHS guidelines, the presence of NPCs is associated with poor retention in care and suboptimal ART adherence2
People living with HIV are more likely than those in the general population to experience NPCs such as anxiety, depression, and insomnia3,4
*Among 725 patients, 88 (SYMTUZA®) and 99 (DRV/c + FTC/TDF) had baseline NPCs.1
In the SYMTUZA® arm, 43% (38/88) had neurologic comorbidities, such as headache (20%) or migraine (6%). In the DRV/c + FTC/TDF arm, 43% (43/99) had neurologic comorbidities, such as headache (21%) or migraine (8%).1
In the SYMTUZA® arm, 64% (56/88) had psychiatric comorbidities, such as depression (35%), anxiety (18%), or insomnia (7%). In the DRV/c + FTC/TDF arm, 70% (69/99) had psychiatric comorbidities, such as depression (27%), anxiety (14%), or insomnia (13%).1
†Compared to those without NPCs at baseline.1
‡This is a post hoc subgroup analysis that is not powered for safety or efficacy; statistical significance has not been established.1
ART=antiretroviral therapy; DHHS=Department of Health and Human Services; DRV/c=darunavir/cobicistat; FTC=emtricitabine; NPC=neurologic/psychiatric comorbidity; TDF=tenofovir disoproxil fumarate.
References: 1. Dunn K, Simonson RB, Luo D, et al. Use of D/C/F/TAF with neurologic/psychiatric comorbidities: AMBER subgroup analysis. Poster presented at: Conference on Retroviruses and Opportunistic Infections; March 8-11, 2020; Boston, MA. 2. Department of Health and Human Services. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Updated January 20, 2022. Accessed March 8, 2022. https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-arv/whats-new-guidelines 3. Lowther K, Selman L, Harding R, Higginson IJ. Experience of persistent psychological symptoms and perceived stigma among people with HIV on antiretroviral therapy (ART): a systematic review. Int J Nurs Stud. 2014;51(8):1171-1189. 4. Fettiplace A, Stainsby C, Winston A, et al. Psychiatric symptoms in patients receiving dolutegravir. J Acquir Immune Defic Syndr. 2017;74(4):423-431.